A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer
Public ClinicalTrials.gov record NCT04100018. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-Blind Study of Nivolumab or Placebo in Combination With Docetaxel, in Men With Metastatic Castration-resistant Prostate Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the safety and effectiveness of nivolumab with docetaxel in men with advanced castration resistant prostate cancer who have progressed after second-generation hormonal manipulation.
Study identification
- NCT ID
- NCT04100018
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,030 participants
Conditions and interventions
Conditions
Interventions
- Nivolumab Biological
- Prednisone Drug
- Docetaxel Drug
- Placebo Other
Biological · Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 6, 2020 (Actual)
- Primary completion
- Jun 1, 2023 (Actual)
- Completion
- Jun 25, 2024 (Actual)
- Last update posted
- Jun 12, 2025
2020 – 2024
United States locations
- U.S. sites
- 45
- U.S. states
- 23
- U.S. cities
- 44
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0305 | Mobile | Alabama | 36608-1753 | — |
| Local Institution - 0012 | Anchorage | Alaska | 99503 | — |
| Local Institution - 0293 | Tucson | Arizona | 85724 | — |
| Local Institution - 0269 | Jonesboro | Arkansas | 72401 | — |
| Local Institution - 0179 | Orange | California | 92868 | — |
| Local Institution - 0055 | Rancho Mirage | California | 92270 | — |
| Local Institution - 0260 | Redondo Beach | California | 90277 | — |
| Local Institution - 0081 | Santa Monica | California | 90404 | — |
| Local Institution - 0087 | Denver | Colorado | 80211-5222 | — |
| Local Institution - 0190 | West Haven | Connecticut | 06516-5907 | — |
| Local Institution - 0366 | Washington D.C. | District of Columbia | 20010-3017 | — |
| Local Institution - 0196 | Hollywood | Florida | 33021 | — |
| Local Institution - 0397 | Jacksonville | Florida | 32256 | — |
| Local Institution - 0164 | Lakeland | Florida | 33805 | — |
| Local Institution - 0181 | Orlando | Florida | 32806 | — |
| Local Institution - 0285 | Pensacola | Florida | 32503 | — |
| Local Institution - 0177 | Weston | Florida | 33331 | — |
| Local Institution - 0117 | Atlanta | Georgia | 30342 | — |
| Local Institution - 0126 | Marietta | Georgia | 30060 | — |
| Local Institution - 0382 | Thomasville | Georgia | 31792 | — |
| Local Institution - 0287 | Niles | Illinois | 60714 | — |
| Local Institution - 0183 | Fort Wayne | Indiana | 46804 | — |
| Local Institution - 0302 | Louisville | Kentucky | 40202 | — |
| Local Institution - 0150 | Baltimore | Maryland | 21201 | — |
| Local Institution - 0332 | Brandywine | Maryland | 20613 | — |
| Local Institution - 0299 | Omaha | Nebraska | 68130 | — |
| Local Institution - 0365 | East Brunswick | New Jersey | 08816 | — |
| Local Institution - 0139 | Florham Park | New Jersey | 07932 | — |
| Local Institution - 0300 | Albany | New York | 12208 | — |
| Local Institution - 0028 | Port Jefferson Station | New York | 11776 | — |
| Local Institution - 0333 | Columbus | Ohio | 43210 | — |
| Local Institution - 0180 | Allentown | Pennsylvania | 18103-6218 | — |
| Local Institution - 0074 | Bala-Cynwyd | Pennsylvania | 19004 | — |
| Local Institution - 0292 | Pittsburgh | Pennsylvania | 15232 | — |
| Local Institution - 0233 | Charleston | South Carolina | 29414 | — |
| Local Institution - 0115 | Myrtle Beach | South Carolina | 29572-4607 | — |
| Local Institution - 0149 | Germantown | Tennessee | 38138 | — |
| Local Institution - 0286 | Austin | Texas | 75251 | — |
| Local Institution - 0303 | Dallas | Texas | 75251 | — |
| Local Institution - 0284 | Houston | Texas | 77024-2843 | — |
| Local Institution - 0195 | Houston | Texas | 77030-3721 | — |
| Local Institution - 0011 | San Antonio | Texas | 78229 | — |
| The University of Texas Health Science Center at Tyler DBA UT Health East Texas Hope Cancer Center | Tyler | Texas | 75701 | — |
| Local Institution - 0110 | Seattle | Washington | 98109 | — |
| Local Institution - 0289 | Spokane | Washington | 99208 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 248 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04100018, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 12, 2025 · Synced Oct 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04100018 live on ClinicalTrials.gov.